Novartis engineers in packaging facility.
Resource: Novartis
Novartis on Friday proposed to present shareholders a person Sandoz share for each five Novartis shares as it claimed it planned to spin off the generic medications division on or all around Oct. 4.
The Swiss drugmaker invited shareholders to an incredible basic meeting on Sept. 15 just after its board of directors unanimously endorsed and advised the proposed spin-off, the enterprise mentioned in a statement.
“If Novartis shareholders approve the proposed distinctive distribution at the EGM, the Spin-off will be executed by the distribution of a dividend-in-form of Sandoz shares to Novartis shareholders, and of Sandoz ADRs (American Depositary Receipts) to Novartis ADR holders,” it explained.
Sandoz, which accounted for about 10% of team main operating revenue of $16.7 billion in 2022, was put underneath a strategic review by Novartis CEO Vas Narasimhan in 2021 adhering to mounting pricing pressures in the U.S. off-patent drug sector.
Novartis announced ideas for the spin-off in August 2022.